By: Jake Smiths

Inflammatory bowel disease (IBD) continues to challenge both clinicians and healthcare systems. With rising patient numbers, unpredictable flare-ups, and the high cost of hospitalizations, the industry is under pressure to find solutions that improve outcomes while managing resources. Patients, too, are increasingly seeking care options that combine scientific rigor with practical support.

In this context, partnerships that integrate clinical research into real-world care pathways are gaining traction. One such initiative is the newly announced pilot between Evinature, a leader in evidence-based nutraceutical therapeutics for gastrointestinal health, and SonarMD, a care-coordination platform for IBD.

Merging Nutraceutical Science with Continuous Care

The pilot will test the integration of Evinature’s CurQD® formulation into SonarMD’s digital care model. CurQD, supported by multiple peer-reviewed studies and referenced in the European ECCO Nutritional Guidelines, has already been adopted by over 40 U.S. medical centers. Unlike traditional nutraceutical use, which often occurs outside clinical oversight, this collaboration embeds the therapy within a provider-coordinated pathway.

Beth Houck, CEO of SonarMD, explained that the partnership represents “an opportunity to provide patients with access to clinically-validated alternatives for their chronic disease.” By leveraging the platform’s continuous monitoring capabilities, providers can track patients’ progress, enhance medication adherence, and potentially reduce the need for costly emergency or inpatient interventions.

Nir Salomon, Co-Founder of Evinature, emphasized the scientific angle: “This collaboration exemplifies our mission to bridge scientific rigor with real-world healthcare delivery. Integrating CurQD into patients’ care pathway allows us to examine how clinically studied nutritional interventions can contribute to improved patient experience and value for providers and payers.”

A Pilot Designed to Generate Actionable Insights

The pilot, launching in early 2026, will enroll eligible patients treated by SonarMD’s partner gastroenterologists. As patients follow the CurQD protocol within the coordinated care framework, SonarMD will collect real-world data on several key metrics:

• Patient well-being and satisfaction
• Treatment adherence
• Reduction in avoidable utilization of high-cost care settings
  

The data collected could provide insights into how nutritional interventions, when guided by clinical evidence and real-time digital support, influence outcomes and healthcare costs. By integrating CurQD into a structured care model, the initiative aims to quantify benefits that have often been anecdotal in the nutraceutical space.

Implications for Value-Based Gastroenterology

Healthcare is increasingly moving toward value-based reimbursement models, where improved patient outcomes and cost efficiency are paramount. SonarMD’s platform already supports these objectives by proactively managing chronic GI conditions and improving provider-payer communication. Integrating a research-backed nutraceutical like CurQD may help extend these benefits, offering a complementary tool for clinicians and payers seeking measurable improvements in care.

If successful, the pilot could inform broader adoption across payer networks and integrated delivery systems, establishing a blueprint for how scientifically validated nutritional interventions can fit into mainstream care pathways.

Toward Smarter, More Integrated IBD Care

The collaboration between Evinature and SonarMD highlights a subtle yet important shift in IBD management: combining technology and evidence-based interventions to improve patient outcomes. By embedding a clinically supported nutraceutical into a digital care pathway, the pilot demonstrates a new model for chronic disease management, one that emphasizes prevention, adherence, and measurable value.

As healthcare systems continue to navigate rising costs and complex patient needs, initiatives like this may define the next generation of integrated, patient-centric care.

Disclaimer: The information presented in this article is intended for general informational purposes and does not constitute medical advice. While the discussed collaboration between Evinature and SonarMD aims to explore new approaches to IBD management, the results of the pilot program and the effectiveness of the interventions described may vary among individuals. Patients are encouraged to consult with their healthcare providers before making any changes to their treatment plans or incorporating new therapies.